A talk with Dr. Jason Valent about ASH abstract 729: Safety, Tolerability, and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

What are the highlights that attendees should take away from your presentation?

The takeaway is the safety of CAEL-101 in combination with CyBorD in AL amyloidosis patients along with early organ responses in patients treated with CAEL-101 and CyBorD.

What is the central question that your study and/or presentation tries to answer?

The central question is what is the recommended phase 3 dose of CAEL-101 in combination with CyBorD?

If applicable, what are the key findings from your study?

Key finding is the safety of CAEL-101 in combination with CyBorD in AL amyloidosis patients along with early organ responses in patients treated with CAEL-101 and CyBorD. Phase 3, double blind, placebo-controlled trials have started based on the results of this Phase 2 study.

What else would you like attendees to know about your presentation?

Phase 3, double blind, placebo-controlled trials have started based on the results of this Phase 2 study.

What are 3–5 questions you would ask attendees about the topic of your presentation to spark an engaging conversation? 

- Were there any cardiac arrhythmias seen in these patients?

- Were there any patients that discontinued treatment due to toxicity from CAEL-101?

- What were the PK assessments like in the patients with significant organ responses?

Dr. Valent has received payment for lectures from the Celgene corporation, Takeda pharmaceuticals, and the Amgen corporation.